Alnylam Pharmaceuticals Inc cuts target price to $410 from $505
ALNY•Related News
CEL-SCI launches Phase 3 confirmatory trial of Multikine in head and neck cancer
CVM•
GRAINS-Soybean and corn up on US weather threat, wheat falls
DBA•
Matinas BioPharma says warrant exercise brings in about $2.6 million cash proceeds
MTNB•
Tactile Medical signs exclusive VA, DoD distribution deal with ElastiMed for MyoSleeve device
TCMD•
OmniAb names Amechi Nwachuku as COO
OABI•